Metastatic melanoma and vemurafenib: novel approaches

被引：3
|
作者：
De Mello, Ramon Andrade [1 ,2 ]
机构：
[1] Portuguese Oncol Inst, Dept Med Oncol, Rua Dr Antonio Bernardino Almeida, P-4200072 Oporto, Portugal
[2] Univ Porto, Fac Med, Dept Med, Oporto, Portugal
来源：
RARE TUMORS | 2012年 / 4卷 / 02期
关键词：
malignant melanoma; dabrafenib; vemurafenib; BRAF V600 mutation; metastatic disease; skin cancer;
D O I：
10.4081/rt.2012.e31
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Metastatic melanoma (MM) presents a treatment challenge to oncologists worldwide. Dacarbazine is the first line chemotherapy treatment for MM, though the overall response rates are very poor. Recently, the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation was found to play a main role in MM. This mutation is present in 40-60% of melanoma patients. Vemurafenib is a BRAF kinase inhibitor that showed impressive results in phase I-III trials and was thus recently approved for the treatment of MM. This paper will briefly focus on vemurafenib in the treatment of MM and highlight concerns
引用
收藏
页码：96 / 97
页数：2
相关论文
共 50 条
  • [21] New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma
    Diamantopoulos, Panagiotis T.
    Lakiotaki, Eleftheria
    Kyriakakis, Georgios
    Gogas, Helen
    MELANOMA RESEARCH, 2020, 30 (02) : 206 - 208
  • [22] Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma
    Yilmaz, Mesut
    Mese, Sermin Guven
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (07) : 1754 - 1758
  • [23] Vemurafenib for the treatment of melanoma
    Jordan, Emmet John
    Kelly, Catherine M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (17) : 2533 - 2543
  • [24] Altered Morphology and Immunohistochemical Characteristics in Metastatic Malignant Melanoma After Therapy With Vemurafenib
    Powell, Matthew R.
    Sheehan, Daniel J.
    Kleven, Daniel T.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2016, 38 (09) : E137 - E139
  • [25] A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
    Deniger, Drew C.
    Kwong, Mei Li M.
    Pasetto, Anna
    Dudley, Mark E.
    Wunderlich, John R.
    Langhan, Michelle M.
    Lee, Chyi-Chia Richard
    Rosenberg, Steven A.
    CLINICAL CANCER RESEARCH, 2017, 23 (02) : 351 - 362
  • [26] Breast lesions of a metastatic melanoma on a radiotherapy territory: Treatment by vemurafenib and carcinologic surgery
    Fernandez, J.
    Montaudie, H.
    Courdi, A.
    Georgiou, C.
    Camuzard, O.
    Chignon-Sicard, B.
    ANNALES DE CHIRURGIE PLASTIQUE ESTHETIQUE, 2016, 61 (01): : 69 - 75
  • [27] BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma
    Lebbe, C.
    How-Kit, A.
    Battistella, M.
    Sadoux, A.
    Podgorniak, M. P.
    Sidina, I.
    Pages, C.
    Roux, J.
    Porcher, R.
    Tost, J.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 96 - 96
  • [28] BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma
    Lebbe, Celeste
    How-Kit, Alexandre
    Battistella, Maxime
    Sadoux, Aurelie
    Podgorniak, Marie-Pierre
    Sidina, Irina
    Pages, Cecile
    Roux, Jennifer
    Porcher, Raphael
    Tost, Jorg
    Mourah, Samia
    MELANOMA RESEARCH, 2014, 24 (04) : 415 - 418
  • [29] Cobimetinib: A Novel MEK Inhibitor for Metastatic Melanoma
    Signorelli, Jessie
    Gandhi, Arpita Shah
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (02) : 146 - 153
  • [30] The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation
    Brown, Michael P.
    Long, Georgina V.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 1 - 15
12345